Lamotrigine (All indications) updated on 04-22-2025

Nervous system anomalies

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17498
R73506		 Wiggs (Epilepsy) (Lamotrigine), 2024 Nervous system malformations early pregnancy population based cohort retrospective unexposed, sick Adjustment: Yes 0.85 [0.18;4.01] -/1,412   -/9,364 - 1,412
ref
S15197
R62328		 Cohen (Lamotrigine) (Mixed indications), 2023 Nervous system malformation 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.41 [0.88;2.27] -/8,339   -/4,866,362 - 8,339
ref
S8924
R48248		 Thomas (Lamotrigine) (Controls unexposed, sick), 2021 Neural malformations 1st trimester prospective cohort unexposed, sick Adjustment: No 6.86 [0.13;349.61] C 0/50   0/340 0 50
ref
S8969
R30377		 Ban (Lamotrigine) (Mixed indications), 2015 Nervous system anomaly 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No 1.28 [0.08;20.59] C 0/273   367/257,153 367 273
ref
Total 4 studies 1.38 [0.88;2.15] 367 10,074
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Wiggs (Epilepsy) (Lamotrigine), 2024Wiggs, 2024 1 0.85[0.18; 4.01]-1,4128%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Cohen (Lamotrigine) (Mixed indications), 2023Cohen, 2023 2 1.41[0.88; 2.27]-8,33988%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Thomas (Lamotrigine) (Controls unexposed, sick), 2021Thomas, 2021 3 6.86[0.13; 349.61]0501%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Ban (Lamotrigine) (Mixed indications), 2015Ban, 2015 4 1.28[0.08; 20.59]3672733%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (4 studies) I2 = 0% 1.38[0.88; 2.15]36710,0740.220.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Epilepsy) (Lamotrigine; 2: Lamotrigine) (Mixed indications; 3: Lamotrigine) (Controls unexposed, sick; 4: Lamotrigine) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.38[0.88; 2.15]36710,0740%NAWiggs (Epilepsy) (Lamotrigine), 2024 Cohen (Lamotrigine) (Mixed indications), 2023 Thomas (Lamotrigine) (Controls unexposed, sick), 2021 Ban (Lamotrigine) (Mixed indications), 2015 4 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.41[0.88; 2.24]3678,6120%NACohen (Lamotrigine) (Mixed indications), 2023 Ban (Lamotrigine) (Mixed indications), 2015 2 unexposed, sickunexposed, sick 1.13[0.27; 4.77]-1,4620%NAWiggs (Epilepsy) (Lamotrigine), 2024 Thomas (Lamotrigine) (Controls unexposed, sick), 2021 2 Tags Adjustment   - No  - No 2.24[0.23; 21.64]3673230%NAThomas (Lamotrigine) (Controls unexposed, sick), 2021 Ban (Lamotrigine) (Mixed indications), 2015 2   - Yes  - Yes 1.35[0.86; 2.12]-9,7510%NAWiggs (Epilepsy) (Lamotrigine), 2024 Cohen (Lamotrigine) (Mixed indications), 2023 2 All studiesAll studies 1.38[0.88; 2.15]36710,0740%NAWiggs (Epilepsy) (Lamotrigine), 2024 Cohen (Lamotrigine) (Mixed indications), 2023 Thomas (Lamotrigine) (Controls unexposed, sick), 2021 Ban (Lamotrigine) (Mixed indications), 2015 40.220.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.75.02.4070.000Wiggs (Epilepsy) (Lamotrigine), 2024Cohen (Lamotrigine) (Mixed indications), 2023Thomas (Lamotrigine) (Controls unexposed, sick), 2021Ban (Lamotrigine) (Mixed indications), 2015

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.41[0.88; 2.24]3678,6120%NACohen (Lamotrigine) (Mixed indications), 2023 Ban (Lamotrigine) (Mixed indications), 2015 2 unexposed, sick controlsunexposed, sick controls 1.13[0.27; 4.77]-1,4620%NAWiggs (Epilepsy) (Lamotrigine), 2024 Thomas (Lamotrigine) (Controls unexposed, sick), 2021 20.510.01.0